Honz Pharmaceutical Co., Ltd. (300086.SZ) engages in the research, development, manufacturing, and sales of pediatric medicines and related healthcare products primarily in China. Founded in 1994 and headquartered in Haikou, Hainan with major operations in Guangzhou, Guangdong, the company maintains five highly automated manufacturing bases across Hainan, Beijing, Hebei, Liaoning, and Guangdong, alongside a new EU GMP-standard facility under construction in Zhongshan, Guangdong. Its core products encompass children's medicines including respiratory treatments such as Ruizhiqing and Kangzhisong, digestive medicines like Kangzhitai, anti-allergic drugs, antibiotics, nutritional supplements, antibacterial and antiviral drugs, antipyretic and analgesic drugs such as Jinlishuang, adult medicines, gynecological drugs, maternal and child health products, and medical devices including masks and protective equipment; the company targets children's health markets with a focus on national branding under the Honz label. Honz Pharmaceutical recently completed the acquisition of Zhongshan Care for Baby Daily Products Co., Ltd. from Hainan Hongshi Investment Co., Ltd. in August 2024 to bolster its maternal and child portfolio, while its controlling shareholder plans to increase its stake by up to 2% through a CNY100 million investment; the firm also earned recognitions such as the 2023 Hainan Top 40 Manufacturing Enterprises and Excellent ESG Case awards, alongside ongoing implementation of its Children's Health Global Strategy.